(Q27851876)

English

ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy (English)

1 reference

13 November 2016

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

13

object named as

Dong-Young Noh

0 references

14

object named as

Yung-Jue Bang

0 references

3

object named as

Seock-Ah Im

0 references

9

object named as

Do-Youn Oh

0 references

7

object named as

Sae-Won Han

0 references

11

object named as

Tae-You Kim

0 references

10

object named as

Wonshik Han

0 references

author name string

Ji-Won Kim

1

0 references

Jee Hyun Kim

2

0 references

Yu Jung Kim

4

0 references

Hye-Suk Han

5

0 references

Jin-Soo Kim

6

0 references

Yoon Kyung Jeon

8

0 references

In Ae Park

12

0 references

publication date

2012

0 references

0 references

83

0 references

218-27

0 references

4

0 references

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Cytotoxicity mediated by human Fc receptors for IgG.

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Critical comments for roles of biomarkers in the diagnosis and treatment of cancer

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1159%2F000341359

21 January 2018

Identifiers

10.1159/000341359

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851876&oldid=1687012525"